On February 12, 2026, Alkermes plc completed its acquisition of Avadel Pharmaceuticals plc, acquiring all outstanding shares at $21.00 per share plus contingent value rights, supported by a $1.525 billion credit agreement. This event is significant for the company as it expands its portfolio and operational capabilities.